BNP Paribas Arbitrage SA decreased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 20.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,783 shares of the company’s stock after selling 3,469 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Ionis Pharmaceuticals were worth $699,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in IONS. Dimensional Fund Advisors LP raised its position in shares of Ionis Pharmaceuticals by 75.0% in the first quarter. Dimensional Fund Advisors LP now owns 170,316 shares of the company’s stock valued at $6,847,000 after purchasing an additional 72,975 shares during the period. Aperio Group LLC raised its position in shares of Ionis Pharmaceuticals by 3.4% in the second quarter. Aperio Group LLC now owns 17,656 shares of the company’s stock valued at $898,000 after purchasing an additional 574 shares during the period. Russell Investments Group Ltd. raised its position in shares of Ionis Pharmaceuticals by 21.4% in the second quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock valued at $1,021,000 after purchasing an additional 3,538 shares during the period. Public Employees Retirement Association of Colorado raised its position in shares of Ionis Pharmaceuticals by 0.3% in the second quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock valued at $1,241,000 after purchasing an additional 65 shares during the period. Finally, World Asset Management Inc raised its position in shares of Ionis Pharmaceuticals by 3.4% in the second quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock valued at $286,000 after purchasing an additional 187 shares during the period. 91.59% of the stock is currently owned by institutional investors.

In related news, CEO Stanley T. Crooke sold 15,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $52.00, for a total transaction of $780,000.00. Following the transaction, the chief executive officer now owns 43,014 shares of the company’s stock, valued at $2,236,728. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Patrick R. O’neil sold 1,000 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $55.50, for a total transaction of $55,500.00. Following the transaction, the senior vice president now directly owns 11,433 shares in the company, valued at approximately $634,531.50. The disclosure for this sale can be found here. Insiders have sold 119,886 shares of company stock worth $6,870,315 in the last ninety days. 2.13% of the stock is currently owned by insiders.

Ionis Pharmaceuticals, Inc. (NASDAQ IONS) opened at $52.46 on Wednesday. Ionis Pharmaceuticals, Inc. has a 52-week low of $37.26 and a 52-week high of $65.51. The stock has a market cap of $6,521.81, a price-to-earnings ratio of 348.40 and a beta of 2.85. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.

A number of equities analysts have recently commented on the stock. Evercore ISI assumed coverage on shares of Ionis Pharmaceuticals in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $65.00 price target on the stock. Stifel Nicolaus reissued a “hold” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, September 12th. Barclays dropped their price target on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a research report on Thursday, September 21st. Jefferies Group reissued an “underperform” rating and issued a $18.00 price target (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, August 10th. Finally, Morgan Stanley lifted their price target on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 8th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $50.31.

WARNING: “BNP Paribas Arbitrage SA Sells 3,469 Shares of Ionis Pharmaceuticals, Inc. (IONS)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/12/06/bnp-paribas-arbitrage-sa-sells-3469-shares-of-ionis-pharmaceuticals-inc-ions.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.